SCHEMBL13638569

SCHEMBL13638569

C=C1CC(Nc2nccc(-c3ccc(C(=O)OCC)s3)n2)CC(C)(C)N1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT3 Q9Y243 11/20 0.37
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
CDK1 P06493 2/20 0.35
CDK4 P11802 2/20 0.35
CCNB1 P14635 2/20 0.35
CCNA2 P20248 2/20 0.35
CCND1 P24385 2/20 0.35
CDK2 P24941 2/20 0.35
CCNA1 P78396 2/20 0.35
TEC P42680 1/20 0.34
TXK P42681 1/20 0.34
BTK Q06187 1/20 0.34
ITK Q08881 1/20 0.34
DGAT1 O75907 1/20 0.34
MAPK8 P45983 2/20 0.34
MAPK9 P45984 2/20 0.34
MAPK10 P53779 1/20 0.33
CCNK O75909 1/20 0.33
CDK12 Q9NYV4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500550 0.87 ALDH1A1 (0.41) AKT3CDK1CDK4CCNB1CCNA2
SCHEMBL13638295 0.87 AKT3 (0.38) AKT3CDK1CDK4CCNB1CCNA2
SCHEMBL13638460 0.87 AKT3 (0.35) AKT3CDK1CDK4CCNB1CCNA2
SCHEMBL14612850 0.86 AKT3 (0.37) AKT3CDK1CDK4CCNB1CCNA2
SCHEMBL13638669 0.85 CDK2 (0.36) AKT3CDK1CDK4CCNB1CCNA2
SCHEMBL13638421 0.84 DGAT1 (0.44) CDK1CDK4CCNB1CCNA2CCND1
SCHEMBL13638474 0.82 AKT3 (0.50) AKT3TECTXKBTKITK
SCHEMBL13638473 0.81 HDAC8 (0.34) CDK1CDK4CCNB1CCNA2CCND1
SCHEMBL13638671 0.81 HDAC8 (0.38) CCNKCDK12
SCHEMBL13638579 0.81 SRC (0.35) AKT3CDK1CDK4CCNB1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed